News

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing describes a recruiting phase 2 study comparing adalimumab with placebo in people with idiopathic REM sleep behavior disorder. The study will assess whether adalimumab can reduce or prevent progression of synuclein-related neurodegeneration, using changes in a Parkinson disease-related imaging pattern as its primary endpoint.

ClinicalTrials.gov: peptide AND aging

ClinicalTrials.gov lists a 90-day randomized, controlled pilot trial of combination gerotherapies as completed. The study was designed to enroll up to 30 participants across three arms to explore longevity-related outcomes; the excerpt provides no results.

ClinicalTrials.gov: peptide AND aging

A study listed on ClinicalTrials.gov is enrolling by invitation to evaluate blood-based measures of organ-specific biological age, particularly in the brain. Researchers aim to examine how these measures relate to established clinical health indicators and respond to treatment with tirzepatide.

ClinicalTrials.gov: peptide AND aging

ClinicalTrials.gov lists a study of enicepatide (CT-388) in participants with overweight or obesity and Type 2 diabetes as completed. The randomized, double-blind, placebo-controlled trial evaluated efficacy and safety across three dose levels; the excerpt provides no results.

ClinicalTrials.gov: elamipretide

ClinicalTrials.gov lists an intermediate-size expanded access protocol for elamipretide with a status of AVAILABLE. The listing states that individual requests undergo careful review and that treating physicians bear full responsibility for treatment and compliance with the protocol.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing marks “Muscle Impact of Treating Osteoporosis” as completed. The study aimed to examine how osteoporosis medications affect muscle health in older adults, but the excerpt provides no results or names of medications studied.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing marked completed describes research on growth hormone’s effects on immune function in healthy men aged 25–50. The protocol includes three studies, but the provided excerpt reports no results.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov-listed study is enrolling by invitation to assess whether geroprotective agents and a peptide-containing skin serum lower measured biological age. Researchers will use gene-activity measurements in skin and blood and assess safety and tolerability; the excerpt reports no results.

ClinicalTrials.gov: peptide AND aging

A recruiting study listed on ClinicalTrials.gov will evaluate whey protein’s effects on glucose control in adults aged 70–90 with type 2 diabetes. The placebo-controlled, partial crossover trial will assess glucose excursions over 7-day periods; the excerpt reports no results.

ClinicalTrials.gov: peptide AND aging

A recruiting study listed on ClinicalTrials.gov will evaluate a 16-week weight-management intervention in adults aged 60 or older with low physical activity and excess body fat. Researchers will compare resistance training alone with added group cognitive behavioral therapy and higher-protein nutritional guidance; the excerpt describes no peptide intervention.

ClinicalTrials.gov: peptide AND aging

A recruiting trial listed on ClinicalTrials.gov is evaluating whether PRAISE, a personalized obstructive sleep apnea treatment adherence model, helps patients follow physician-recommended positive airway pressure treatment. The title also identifies Alzheimer's disease biomarkers and cognition among Black participants as study topics; no results or peptide intervention are described.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing describes a trial comparing ketone monoester plus protein with protein alone after resistance exercise in older trained males. The trial is not yet recruiting and will assess phenylalanine metabolism and measures of protein breakdown; no results are reported.

ClinicalTrials.gov: peptide AND aging

A completed study listed on ClinicalTrials.gov evaluated an AI-personalized skincare regimen in women aged 35–65 with mild-to-moderate facial photoaging. The 12-week regimen included night creams containing a triple-peptide complex; the excerpt describes assessments of skin aging and tolerability but reports no results.

ClinicalTrials.gov: peptide AND aging

A recruiting randomized trial listed on ClinicalTrials.gov aims to test a 12-week diet and exercise intervention in 80 adults aged 50 and older with obesity and insulin resistance. Researchers will assess body composition, muscle function, and energy balance; the excerpt describes no peptide intervention or results.

ClinicalTrials.gov: peptide AND aging

A recruiting trial listed on ClinicalTrials.gov will study Adapted Argentine Tango for chemotherapy-induced neuropathy in breast cancer survivors. The listing states that up to 80% of these survivors experience neuropathy and describes an intervention targeting motor control, symptoms, and treatment participation.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing marks as completed a study of how roflumilast and sitagliptin affect blood sugar, insulin, and gut hormones in healthy volunteers aged 21–55. Researchers investigated whether the drugs may increase GLP-1; the provided excerpt contains no results.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing describes a randomized, double-blind, placebo-controlled trial of Vicia faba L.-derived peptides combined with resistance training in approximately 100 adults aged 60 or older. The study is enrolling by invitation and will assess physical, cognitive, and quality-of-life outcomes.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing reports that a study of tirzepatide in post-menopausal women with obesity is recruiting. The study aims to assess effects on menopausal vasomotor symptoms and measures of biological aging.

FDA press releases

The FDA announced a request for information on approaches it is considering for designing early-phase clinical trials of ibogaine drug products. The agency is seeking public input on those approaches.

ClinicalTrials.gov: peptide AND aging

A ClinicalTrials.gov listing describes a planned 16-week randomized trial of resistance training, whole-body electrical stimulation, and dietary protein guidance in 36 older adults with overweight or obesity. The study is not yet recruiting and will assess body composition, physical function, and quality of life; no peptide intervention is described.